Younossi Z, Anstee Q, Marietti M et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2017;14:11–20.

Google Scholar 

John Hopkins Medicine. Nonalcoholic fatty liver disease. John Hopkins Health (2023, Nov 2). Retrieved from https://www.hopkinsmedicine.org/health/conditions-and-diseases/nonalcoholic-fatty-liver-disease#:~:text=Health%20care%20providers%20divide%20fatty,called%20nonalcoholic%20steatohepatitis%20(NASH).

U.S. Department of Health and Human Services. Nonalcoholic fatty liver disease (NAFLD) & NASH. National Institute of Diabetes and Digestive and Kidney Diseases (2023, Sept 10). Retrieved from https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/definition-facts.

Rinella M, Neuschwander-Tetri B, Siddiqui M et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatol AASLD 2023;78:1797–1835.

Article  Google Scholar 

Bansal MB. Steatotic liver disease [PowerPoint slides]. Presented at Transplant Hepatology Summer Seminar Series, Mount Sinai Health System (2023, Aug 25).

Ma N, Yip R, Lewis S et al. Environmental exposures are important risk factors for advanced liver fibrosis in African American adults. JHEP Rep. 2023;5:537–545.

Google Scholar 

Dulai PS, Singh S, Patel J et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557–1565.

Article  CAS  PubMed  Google Scholar 

Bansal MB. Screening at risk populations for NASH with advanced fibrosis and linkage to care [PowerPoint slides]. Presented at MSW/MSM DGIM Grand Rounds, Mount Sinai Health System (2022, Dec 6).

Long TM, Noureddin M, Lim KJ. AGA clinical practice update: diagnosis and management of Non-Alcoholic Fatty Liver Disease (NAFLD) in lean individuals: expert review. Gastroenterology. 2022;163:764–774.

Article  PubMed  Google Scholar 

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797–1835.

Article  PubMed  Google Scholar 

Adams LA, Feldstein AE. Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Rev Gastroenterol Hepatol. 2014;4:623–635.

Article  Google Scholar 

Tun KM, Noureddin N, Noureddin M. Noninvasive tests in the evaluation of nonalcoholic fatty liver disease: a review. Clin Liver Dis. 2023;22:103–112.

Article  Google Scholar 

Bansal MB. INEDSYS Library. From pathogenesis and treatment of hepatic fibrosis: is reversal of cirrhosis a myth? [YouTube video] (2022, Aug 16). Retrieved from https://www.youtube.com/watch?v=UEPhGJ9nuMQ

Conklin DJ. From lung to liver: How does airborne particulate matter trigger NASH and systemic insulin resistance? J Hepatol. 2013;58:8–10.

Article  CAS  PubMed  Google Scholar 

Kallwitz E, Daviglus M, Allison M et al. Prevalence of suspected nonalcoholic fatty liver disease in Hispanic/Latino individuals differs by heritage. Clin Gastroenterol Hepatol. 2015;13:569–576.

Article  PubMed  Google Scholar 

Reja A, Makar M, Visaria A et al. Blood lead level is associated with advanced liver fibrosis in patients with non-alcoholic fatty liver disease: a nationwide survey (NHANES 2011–2016). Ann Hepatol. 2020;19:404–410.

Article  CAS  PubMed  Google Scholar 

New York City Open Data. 2020 Community District Tabulation Areas (CDTAs). Retrieved from 2020 Community District Tabulation Areas (CDTAs)—Mapped, NYC Open Data (cityofnewyork.us) (2023, Nov 2).

NYC Department of City Planning. NYC 2020 Census Geographic Reconfiguration Atlas, Maps comparing 2020 census geographies with their 2010 census counterparts (2023, Nov 2). Retrieved from https://storymaps.arcgis.com/stories/0e4344ea8fec44ee89f881e705edf206.

New York City Department of Housing Preservation and Development (HPD) and the Department of City Planning (DCP). Equitable development data explorer. NYC Department of City Planning, Housing Preservation & Development (2023, Nov 2). Retrieved from https://equitableexplorer.planning.nyc.gov/map/data/district?geoid=3805.

Environment and Health Data portal. New York City Community Air Survey (NYCCAS). NYCCAS Report: 2008–2021 (2023, Nov 2). Retrieved from https://a816-dohbesp.nyc.gov/IndicatorPublic/beta/key-topics/airquality/nyccas/.

National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN)-recommended Common Data Elements (CDEs) of Substance Use Disorders. Instrument: AUDIT-C Questionnaire (2025 Feb 4). Retrieved from https://cde.nida.nih.gov/instrument/f229c68a-67ce-9a58-e040-bb89ad432be4

Brokamp C, Andrew FB, Neera KG et al. Material community deprivation and hospital utilization during the first year of life: an urban population-based cohort study. Ann Epidemiol. 2019;30:37–43.

Article  PubMed  Google Scholar 

Hu W, Liu Z, Hao H et al. Correlation between income and non-alcoholic fatty liver disease in a Chinese population. Ann d’Endocrinol 2020;81:561–566.

Article  Google Scholar 

Guo B, Guo Y, Nima Q et al. Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease. J. Hepatol. 2022;76:518–525.

Article  CAS  PubMed  Google Scholar 

Wallwork RS, Colicino E, Zhong J, Kloog I, Coull BA, Vokonas P, Schwartz JD, Baccarelli AA. Ambient fine particulate matter, outdoor temperature, and risk of metabolic syndrome. Am J Epidemiol. 2017;185:30–39. https://doi.org/10.1093/aje/kww157.

Article  PubMed  Google Scholar 

Jirapatnakul A, Yip R, Branch AD, Lewis S, Crane M, Yankelevitz DF, Henschke I. Dose-response relationship between World Trade Center dust exposure and hepatic steatosis. Am J Ind Med. 2021;64:837–844.

Article  PubMed  Google Scholar 

Sun Q, Yue P, Deiuliis JA et al. Ambient air pollution exaggerates adipose inflammation and insulin resistance in a mouse model of diet-induced obesity. Circulation 2009;119:538–546.

Article  CAS  PubMed  Google Scholar 

Huang A, Zou C, Dai Z et al. Mild-moderate alcohol consumption and diabetes are associated with liver fibrosis in patients with biopsy-proven MASLD. Front Pharmacol. 2024;5:1437479.

Article  Google Scholar 

Abul-Husn N, Cheng X, Li A et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med. 2018;378:1096–1106.

Article  CAS  PubMed  PubMed Central  Google Scholar